Dyadic announces initiation of dosing of first-in-human phase 1 trial to demonstrate clinical safety and antibody response in humans for dyai-100 covid-19 recombinant protein rbd booster vaccine candidate

Jupiter, fla., jan. 24, 2023 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial protein production platforms today announced that, in line with the timing announced during management's q3 earnings call, it has initiated dosing in its phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for the dyai-100 covid-19 recombinant protein receptor binding domain (rbd) booster vaccine candidate.
DYAI Ratings Summary
DYAI Quant Ranking